Drugs / NWRD09
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07710664 | Jul → Dec 2026 expected | human papilloma virus infection | Newish Biotech (Wuxi) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07047989 | Jun 2025 → Jul 2026 overdue | cervical intraepithelial neoplasia grade 2/3 | Newish Biotech (Wuxi) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07536282 | Oct 2026 → Sep 2027 expected | human papilloma virus infection | Newish Biotech (Wuxi) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07712692 | Aug 2026 → Jun 2027 expected | cervical intraepithelial neoplasia grade 2/3 | Newish Biotech (Wuxi) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07710703 | Feb → Nov 2026 expected | — | Newish Biotech (Wuxi) Co., Ltd. | Recruiting | No outcome recorded |
| — | NCT06741150 | Jun 2024 → Dec 2025 overdue | cervical cancer, intraepithelial neoplasia | Newish Technology (Beijing) Co., Ltd. | Recruiting | No outcome recorded |
| — | NCT07092007 | Jun 2024 → Dec 2025 overdue | cervical cancer, intraepithelial neoplasia | Newish Technology (Beijing) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NWRD09 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07710703 ↗ |
| Modality | Messenger RNA (mRNA) | “HPV-16 targeted mRNA vaccine” NCT06741150 ↗ |
| Route | Intramuscular | “administered NWRD09 by intramuscular injection” NCT06741150 ↗ |